These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26389682)

  • 81. Treatment Options for Agitation in Dementia.
    Ringman JM; Schneider L
    Curr Treat Options Neurol; 2019 Jun; 21(7):30. PubMed ID: 31231784
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates.
    Marcinkowska M; Śniecikowska J; Fajkis N; Paśko P; Franczyk W; Kołaczkowski M
    CNS Drugs; 2020 Mar; 34(3):243-268. PubMed ID: 32052375
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.
    Ballard C; Creese B; Corbett A; Aarsland D
    Expert Opin Drug Saf; 2011 Jan; 10(1):35-43. PubMed ID: 20684745
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.
    Lozupone M; La Montagna M; D'Urso F; Piccininni C; Sardone R; Dibello V; Giannelli G; Solfrizzi V; Greco A; Daniele A; Quaranta N; Seripa D; Bellomo A; Logroscino G; Panza F
    Expert Opin Pharmacother; 2018 Jun; 19(8):823-842. PubMed ID: 29726758
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Combination drug shows promise for treating agitation in patients with Alzheimer's disease.
    Wise J
    BMJ; 2015 Sep; 351():h5015. PubMed ID: 26400972
    [No Abstract]   [Full Text] [Related]  

  • 87. Pharmacological treatment of Alzheimer's Disease.
    Bianchetti A; Ranieri P; Margiotta A; Trabucchi M
    Aging Clin Exp Res; 2006 Apr; 18(2):158-62. PubMed ID: 16702787
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
    Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
    Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Narrative Review of Studies Comparing Efficacy and Safety of Citalopram with Atypical Antipsychotics for Agitation in Behavioral and Psychological Symptoms of Dementia (BPSD).
    Qasim HS; Simpson MD
    Pharmacy (Basel); 2022 Jun; 10(3):. PubMed ID: 35736776
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Antipsychotics in geriatric institutions].
    Szulik J
    Vertex; 2007; 18(76):454-60. PubMed ID: 18273435
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Benefits and harms of atypical antipsychotics for agitation in adults with dementia.
    Farlow MR; Shamliyan TA
    Eur Neuropsychopharmacol; 2017 Mar; 27(3):217-231. PubMed ID: 28111239
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.
    Wang J; Yu JT; Wang HF; Meng XF; Wang C; Tan CC; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):101-9. PubMed ID: 24876182
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.
    Wolinsky D; Drake K; Bostwick J
    Curr Psychiatry Rep; 2018 Oct; 20(12):117. PubMed ID: 30367272
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Adjunctive therapy in patients with Alzheimer's disease. A practical approach.
    Corey-Bloom J; Galasko D
    Drugs Aging; 1995 Aug; 7(2):79-87. PubMed ID: 7579786
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
    Žmuc Veranič L; Pregelj P; Jerin A
    Psychogeriatrics; 2016 Nov; 16(6):384-385. PubMed ID: 26551073
    [No Abstract]   [Full Text] [Related]  

  • 97. Principal components analysis of agitation outcomes in Alzheimer's disease.
    Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
    Gleason RP; Schneider LS
    J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
    Newell J; Yesavage JA; Taylor JL; Kraemer HC; Munro CA; Friedman L; Rosenberg PB; Madore M; Chao SZ; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Mar; 74():17-21. PubMed ID: 26736036
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Neuropsychiatric symptoms in dementia: importance and treatment considerations.
    Ballard C; Day S; Sharp S; Wing G; Sorensen S
    Int Rev Psychiatry; 2008 Aug; 20(4):396-404. PubMed ID: 18925489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.